OFF THE SHELF DELIVERING THE VACCINE PROMISE. Anders Hedegaard, President & CEO



Relaterede dokumenter
Generalforsamling 2013

..IR funktionen Rolf Sass Sørensen, VP, IR & Communications DIRF, 14. oktober 2011

EN GLOBALT FØRENDE VACCINELEVERANDØR

BioPorto. 25. november 2015 Smallcap seminar ØU

Ekstraordinær Generalforsamling Vilvorde Kursuscenter 27. maj 2009

EN GLOBALT FØRENDE VACCINELEVERANDØR

BioPorto. BioPorto efter FDA-svar: en ny dagsorden

Langsigtet vedligeholds- planlægning baseret på risikoanalyse og FMECA. Maintenance Engineer Kren Krog Jensen Bavarian Nordic A/S

BAVARIAN NORDIC. Omsætning og resultat E E

BioPorto. Investormøde Q2

BioPorto BioPorto & vækstmulighederne i USA Dansk Aktionærforening, 2. juni 2015

Investormøde 7. november 2014 Første tre kvartaler CEO, Peter M. Eriksen CFO, Otto Rasmussen EVP Sales, Finn Fjorder

Generalized Probit Model in Design of Dose Finding Experiments. Yuehui Wu Valerii V. Fedorov RSU, GlaxoSmithKline, US

BioPorto. Investormøde Q3

BioPorto. Eksekvering og klargøring til vækst

VACCINER TIL FOREBYGGELSE AF LIVSTRUENDE INFEKTIONSSYGDOMME OG BEHANDLING AF KRÆFT

BAVARIAN NORDIC. Omsætning og resultat E E

VOKSEVÆRK I VACCINEPIPELINEN ROLF SASS SØRENSEN, VICE PRESIDENT INVESTOR RELATIONS & COMMUNICATIONS INVESTORDAGEN AARHUS 7.

ORDINÆR GENERALFORSAMLING 2014

Fra risiko til beredskab virksomhedens perspektiv. Vibeke Østergaard Thomsen Sikkerhedsleder

United Nations Secretariat Procurement Division

BioPorto. Eksekvering af vækststrategi for fokuseret diagnostisk portefølje

Handelsbanken. Lennart Francke, Head of Accounting and Control. UBS Annual Nordic Financial Service Conference August 25, 2005

applies equally to HRT and tibolone this should be made clear by replacing HRT with HRT or tibolone in the tibolone SmPC.

VÆKST I VACCINEPIPELINEN

SIDEN SIDST: fantastisk år. 2 væsentlige. partneraftaler. 3 x markedsværdi

Nyhedsmail, december 2013 (scroll down for English version)

ESG reporting meeting investors needs

Experience. Knowledge. Business. Across media and regions.

Portal Registration. Check Junk Mail for activation . 1 Click the hyperlink to take you back to the portal to confirm your registration

Financing and procurement models for light rails in a new financial landscape

Strategic Capital ApS has requested Danionics A/S to make the following announcement prior to the annual general meeting on 23 April 2013:

Bestyrelsens beretning

Bestyrelsens beretning

Mandara. PebbleCreek. Tradition Series. 1,884 sq. ft robson.com. Exterior Design A. Exterior Design B.

3Q11 Investor Conference. October 27, 2011

Masters Thesis - registration form Kandidatafhandling registreringsformular

10. april 2014 BIOPORTO A/S ORDINÆR GENERALFORSAMLING

Status of & Budget Presentation. December 11, 2018

Unitel EDI MT940 June Based on: SWIFT Standards - Category 9 MT940 Customer Statement Message (January 2004)

ÆLDRE OG KRÆFT. Introduktion. Trine Lembrecht Jørgensen Læge, ph.d., post. doc. University of Southern Denmark. Odense University Hospital

Aktivering af Survey funktionalitet

Behandlingsfremskridt inden for kræft

Evaluating Germplasm for Resistance to Reniform Nematode. D. B. Weaver and K. S. Lawrence Auburn University

From innovation to market

Alfa-1-antitrysin mangel hos børn. Elisabeth Stenbøg, Afd.læge, PhD Børneafd. A, AUH

Small Autonomous Devices in civil Engineering. Uses and requirements. By Peter H. Møller Rambøll

INVESTORDAGEN KØBENHAVN 19. SEPTEMBER 2017

Privat-, statslig- eller regional institution m.v. Andet Added Bekaempelsesudfoerende: string No Label: Bekæmpelsesudførende

Skriftlig Eksamen Kombinatorik, Sandsynlighed og Randomiserede Algoritmer (DM528)

Project Step 7. Behavioral modeling of a dual ported register set. 1/8/ L11 Project Step 5 Copyright Joanne DeGroat, ECE, OSU 1

ÅRSREGNSKAB Pressemøde. Peter Straarup. Ordførende direktør. Tonny Thierry Andersen. Koncernøkonomidirektør. 4. februar 2010

Basic statistics for experimental medical researchers

Predictors of chemotherapy induced toxicity in 421 patients with metastatic castration resistant prostate cancer results from a single institution

Når behandlingen flytter hjem: muligheder og risici. Konsensusmøde om det borgernære sundhedsvæsen. Henning Boje Andersen

Hvor mange har egentlig kræft?

BioPorto. InvestorDagen Dansk Aktionærforening

LAW FIRM ASSOCIATION FOR

Melbourne Mercer Global Pension Index

BILAG 8.1.F TIL VEDTÆGTER FOR EXHIBIT 8.1.F TO THE ARTICLES OF ASSOCIATION FOR

Medinddragelse af patienter i forskningsprocessen. Hanne Konradsen Lektor, Karolinska Institutet Stockholm

Impala Platinum 10 Shaft Decline Analyst Visit - 25 October 2002

Supplier development så langt kan man nå i samarbejdet mellem kunde og leverandør. Søren Jepsen 13. Juni 2013

Mandara. PebbleCreek. Tradition Series. 1,884 sq. ft robson.com. Exterior Design A. Exterior Design B.

Mission and Vision. ISPE Nordic PAT COP Marts Jesper Wagner, AN GROUP A/S, Mejeribakken 8, 3540 Lynge, Denmark

User Manual for LTC IGNOU

Manuel behandling for patienter med hofteartrose

System Management Principles Statement

Financial Literacy among 5-7 years old children

November hilsner fra NORDJYSKE Medier, Distributionen

Fejlbeskeder i SMDB. Business Rules Fejlbesked Kommentar. Validate Business Rules. Request- ValidateRequestRegist ration (Rules :1)


Sport for the elderly

OVERORDNEDE RETNINGSLINJER FOR INCITAMENTSAFLØNNING AF DIREKTIONEN LAND & LEISURE A/S

System Management Principles Statement

Central Statistical Agency.

INVESTORDAGEN AARHUS 13. JUNI 2017

Introduktion. Stærk fremgang i pipelinen med øget fokus på cancervacciner

Director Onboarding Værktøj til at sikre at nye bestyrelsesmedlemmer hurtigt får indsigt og kommer up to speed

APPENDIX E.3 SHADOW FLICKER CALCULATUIONS. 70 m TOWERS & 56 m BLADES

BILAG 8.1.B TIL VEDTÆGTER FOR EXHIBIT 8.1.B TO THE ARTICLES OF ASSOCIATION FOR

System Management Principles Statement

Vores mange brugere på musskema.dk er rigtig gode til at komme med kvalificerede ønsker og behov.

Agenda Subject Time Status Annex Comments

Measuring the Impact of Bicycle Marketing Messages. Thomas Krag Mobility Advice Trafikdage i Aalborg,

Sikkerhed & Revision 2013

BioPorto. Vækst og klargøring til US roll-out

Prioritering eller ej? Hvad er Konsekvensen? Jens Winther Jensen. Lægeforeningen

Regnskab for 1. halvår 2012

Valg af Automationsplatform

Bookingmuligheder for professionelle brugere i Dansehallerne

HA-SPAD MEDIA KIT

Design til digitale kommunikationsplatforme-f2013

Nordisk Tænketank for Velfærdsteknologi

Ansøgning om godkendelse af pesticider. Gælder fra 1. januar 2014.

To the reader: Information regarding this document

Business Rules Fejlbesked Kommentar

Brüel & Kjær cooperation with Turbomeca - France

Varenr.: højre venstre º højre med coating º venstre med coating

Engelsk. Niveau C. De Merkantile Erhvervsuddannelser September Casebaseret eksamen. og

Transkript:

OFF THE SHELF DELIVERING THE VACCINE PROMISE Anders Hedegaard, President & CEO February 2010 1

Bavarian Nordic Cancer Vaccines Therapeutics Infectious Diseases Klassiske Vacciner PROSTVAC - Standard immunterapi til fremskreden prostatacancer Fase 3 påbegyndes i 2011 Stærke data i et blockbuster marked: 8,5 mdr. forøget overlevelse CRADA med NCI IMVAMUNE - Næste generation koppevaccine Fuldt finansieret biodefence program med den amerikanske regering Igangværende kontrakter med USA 20 mio. doser ~ USD 505 mio. + option 60 mio. doser ~ USD 1,1 mia. International virksomhed Fuldt integreret virksomhed fra R&D til produktion og salg Stærk IP position på førende projekter og MVA-BN teknologien Noteret på NASDAQ OMX: BAVA Market cap (Feb-2011): DKK 3.3 mia. 400+ medarbejdere Industrial Scale Production (Denmark) R&D Infectious Diseases (Munich) Pilot Manufacturing (Berlin) R&D Cancer (California) Governmental Affairs (Washington)

Pipeline Cancer Vaccines PROSTVAC MVA-BN PRO MVA-BN HER2 Præklinisk Fase I Fase I/II Fase II Fase III Marked Næste milepæl Fase III (2011) Endelige data (2011) Foreløbige data (2011) Infectious Diseases IMVAMUNE Miltbrand HIV Mæslinger/RSV Fase III (2011) Fase I (2011) Fase II partner Fase I data (2011) 3

Cancer Vaccines Førende leverandør af terapeutiske vacciner inden for største cancertyper Førende produkt PROSTVAC - Standard immunterapi til fremskreden prostatacancer Stærke data i et blockbuster marked 8,5 mdr. forøget overlevelse = 50 % øget levetid Mål PROSTVAC i fase III og på markedet med partner Udvide pipelinen med flere mellem-fase projekter Udvikle nye vaccinerkandidater PROSTVAC MVA-BN PRO MVA-BN HER2 Prostatacancer Prostatacancer Brystcancer Fase I Fase I/II Fase II Fase III Næste milepæl Fase III (2011) Endelige data (2011) Foreløbige data (2011) 4

1 ud af 6 mænd får prostatacancer 1 af 6 af disse dør af prostatacancer PROSTVAC 5

Prostate cancer - high unmet medical need Metastatic disease is incurable Common cause of death in men >250,000 deaths/year (WW) Increase in cases (780,000 annually) Treated with chemotherapy (limited life-extension and severe side effects) Provenge recently approved as first immunotherapy for this patient population 6 Global Cancer Facts & Figures 2007, American Cancer Society

Udviklingen i prostatacancer Tumor størrelse og aktivitet Hormonbehandling Kemoterapi start Død Lokal behandling Ingen smerter Hormonafhængig Ikke-metastatisk Smerter Hormonresistent Metastatisk 7

PROSTVAC An innovative recombinant therapeutic vaccine Subcutaneous injection Off-the-shelf vial vaccine that does not require individualised therapy Targets a unique cancer cell antigen (PSA) And encodes co-stimulatory molecules Is a sequentially dosed combination of two different Poxviruses Phase II results demonstrated extended survival of 8.5 months Extended median overall survival of 8.5 months compared to placebo in a Phase 2 randomized, placebo-controlled study that enrolled patients with mcprc Vaccinia-PSA-TRICOM Fowlpox-PSA-TRICOM 8

PROSTVAC Phase 2 Multicenter Phase 2 randomized, placebo-controlled double-blind 125 patients enrolled 43 sites 83 PROSTVAC-VF + GM-CSF 41 empty vectors (VVwt-fowlpox) + placebo Accrual: November 2003 to July 2005 Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration- Resistant Prostate Cancer Journal of Clinical Oncology, 2010, Jan 25 9

PROSTVAC Phase 2 results survival (% of patients) 100 80 60 25.1 months Significantly extended overall survival N Deaths Median Control 40 37 16.6 PROSTVAC 82 65 25.1 40 20 16.6 months Δ 8.5 months Hazard ratio 0.56 (95% CI 0.37 0.85) p=0.0061 0 months 0 12 24 36 48 60 10 Kantoff et al. J Clin Oncol, January 2010

Regulatory progress of PROSTVAC End of Phase 2 meeting concluded FDA and EMEA endorse the overall Phase 3 plan Fast Track status granted by the FDA Expedited review process BLA can be submitted on a rolling basis, allowing the FDA to review sections of the BLA in advance of receiving the complete submission Special Protocol Assessment (SPA) SPA agreement with FDA on Phase 3 protocol received in Dec-2010 Phase 3 design and endpoints agreed A successful Phase 3 outcome could form the primary clinical basis of product approval under a Biologics License Application. 11

Phase 3 design and endpoints Phase 3 design (according to SPA) Strongly powered, single global, placebo-controlled study ~1,200 patients Asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer Three study arms: PROSTVAC + GM-CSF PROSTVAC + GM-CSF Placebo PROSTVAC Placebo + GM-CSF Placebo Endpoints Primary endpoint is overall survival (OS). For the study outcome to be positive, either one or both of the treatment arms must be superior to placebo. Each comparison requires 534 deaths with sensitivity for estimated death hazard ratios of 0.82 or less. 12

PROSTVAC has potential PROSTVAC advantages Efficacy and safety demonstrated in a rigorous Phase 2 program Phase 2 studies show a clinically relevant survival benefit Potential application in both early - and late-stage prostate cancer Phase 3 in preparation with expected initiation in 2011 Only off-the-shelf therapeutic vaccine in development for prostate cancer Clear cost and practicality advantages over autologous competitors Likely to be the second therapeutic vaccine to market Riding the wave of the first approved prostate cancer vaccine - opportunity to enter a vaccine-receptive market shaped by the first entrant 13

PROSTVAC has potential Improved survival benefit and better quality of life Compared with current chemotherapies, PROSTVAC potentially offers improved survival benefit and better quality of life Can potentially be combined with other modalities such as taxotere or abiraterone Cancer market is occupied by premium products at premium prices Avastin can cost up to US$100,000/year 1 Herceptin can cost up to US$65,000/year 2 Provenge cost up to US$93,000 for a full course of treatment First label in mcrpc Subsequent move into early-stage disease supported by study data 1 The Evidence Gap Costly Cancer Drug Offers Hope, but Also a Dilemma, New York Times July 8, 2008 2 Studies Find Trastuzumab (Herceptin) Cost-Effective As Treatment for Women with Early-Stage HER2-Positive Breast Cancer, ASCO February 16, 2007 14

Infectious Diseases Førende leverandør af vacciner mod infektionssygdomme Førende produkt IMVAMUNE - Næste generation koppevaccine med uovertruffen sikkerhed og effektivitety Fuldt finansieret biodefence program og igangværende kontrakter med USA 20 mio. doser ~ USD 505 mio. + option 60 mio. doser ~ USD 1,1 mia. Mål Succesfulde leverancer af IMVAMUNE til den amerikanske regering Opnå nye kontrakter med USA Udvide pipelinen med flere mellem-fase projekter Udvikle nye vaccinekandidater IMVAMUNE MVA-BN Anthrax MVA-BN HIV multiantigen MVA-BN Measles/RSV Kopper Miltbrand HIV RSV Fase I Fase I/II Fase II Fase III Næste milepæl Fase III (2011) Fase I (2011) Fase II partner Fase I data (2011) 15

IMVAMUNE 16

Limitations of current smallpox vaccines Currently stockpiled vaccines are based on a replicating vaccinia virus: DryVax, ACAM2000, LC16m8, Elstree-BN Side effects All have been shown to produce some/all of following side effects: Encephalitis, generalized vaccinia, inadvertent infection skin and eyes/self and contacts, myo-pericarditis 25% 25% of the population cannot receive current smallpox vaccines Young, elderly, people with a history of atopic disorders (e.g. eczema), HIV or AIDS, cancer patients 17

IMVAMUNE advantages Based on a non-replicating virus Safety Far superior safety profile than the old vaccines More than 3,200 individuals have been vaccinated Well tolerated even in immune-compromised No product-related severe adverse events reported Efficacy Induces faster protective immune response Protects already after 3-4 days vs. 10-12 days with the traditional vaccines* 18 *Pre-clinical data

Contracts with the US government Secured Optional RFP-1 RFP-2 RFP-3 Base contract Early clinical and technical development 500,000 doses of IMVAMUNE delivered Clinical studies will support Emergency Use 20 million doses of IMVAMUNE Licensing for healthy individuals > USD 144m USD 505m Option 60 million doses of IMVAMUNE Licensing for immune compromised > USD 1,100m RFP Freeze-dried Validation of production process Preclinical and clinical development to support emergency use USD 40m ~USD 690m > USD 1,100m 19

IMVAMUNE deliveries to the US Deliveries to the US Strategic National Stockpile 1.7m doses delivered and invoiced to date (Nov-10) 2m doses will be delivered in 2010 Remaining 18m doses to be delivered between 2011 and 2013 Exact delivery schedule is expected to be determined during 2011 2010: 2m doses 2011-2013: 18m doses 20

Phase III status and next step Phase III protocols submitted to the FDA awaiting review Final clinical and preclinical protocols for Phase III submitted to the FDA Once the protocols have been reviewed, a Vaccines Related Biological Product Advisory Committee (VRBPAC) will be scheduled by the FDA to ratify the license strategy. Upon ratification, Phase III can be initiated. 21

Financial Outlook Revenue Result (loss) before tax Cash preparedness, year-end All numbers are approximate 2010 DKK 325 m DKK -450 m DKK 450 m 22

Recent highlights PROSTVAC regulatory path outlined SPA agreement with FDA on Phase 3 protocol in place Fast track status granted CRO for Phase 3 engaged identification of centres IMVAMUNE deliveries to the US initiated Deliveries to the US Strategic National Stockpile initiated 2 million doses to be delivered in 2010 18 million doses to be delivered in 2011-2013 Phase 3 protocols submitted to the FDA 23

Future milestones PROSTVAC Phase 3 initiation Commercial partner on PROSTVAC IMVAMUNE NDS submission to Canada Government funding opportunities, current and future projects Decision on new pipeline opportunities 24

The Bavarian Nordic share 300 250 200 150 100 50 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 BAVA.CO Institutions, Funds 64% Private 24% Non-reg. 12% No. of shares, 89% free-float 13m Registered share capital 88% No. of registered shareholders 17,600 Distribution of reg. shares DK: 75%, ROW: 25% 25 Largest shareholders (>5%) A.J. Aamund A/S, ATP Share price (8 Feb 2011) DKK 252.50 High/low 52 weeks 293 / 167 Market cap DKK 3.3bn Net free liquidity per share DKK 25 (30 Sep 2010) Volume (3m, daily average) 27,000

This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake 26 no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.